2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.Peer-Reviewed Original ResearchConceptsCD8+ T cellsImmune-related adverse eventsImmune checkpoint inhibitorsT cellsCheckpoint inhibitorsAssociated with immune-related adverse eventsPD-1 inhibitor therapyT-cell axisEnhanced Th17Antitumor immunityCTLA-4PD-1Inhibitor therapyImmunomodulatory therapyTCR repertoirePredictive biomarkersPeripheral bloodMyeloid cellsAdverse eventsCell signaturesCancer therapyInflammatory arthritisInflamed jointsTherapyTherapeutic target
2020
RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.
Kim S, Murphy W, Aparicio A, Subudhi S. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. Journal Of Immunotherapy And Precision Oncology 2020, 3: 128-132. PMID: 35663254, PMCID: PMC9165580, DOI: 10.36401/jipo-20-2.Peer-Reviewed Original ResearchSecond-generation hormone therapyImmune-related adverse eventsMetastatic prostate cancerImmune checkpoint inhibitorsProstate cancerHormone therapyCase of RS3PEPitting edemaRemitting seronegative symmetrical synovitisCycles of ipilimumabDiscontinued 2 monthsRadium-223 treatmentDiagnosis of RS3PEOptimal therapeutic strategyWeeks of treatmentCheckpoint inhibitorsAntitumor immunityRadium-223Bone scanInflammatory toxicityPredictive biomarkersIpilimumabActive inflammationSymmetrical synovitisAdverse events